Intervest’s 40 Billion Won Bet on AimedBio Nears ‘Tenbagger’ Status as Shares Surge
AimedBio shares have soared since listing, positioning Intervest for a potential tenfold return on its 40 billion won investment, pending lock-up expirations.
AimedBio will debut on KOSDAQ this week, leading a busy IPO calendar with five retail subscriptions and two institutional bookbuildings, highlighting strong investor demand in South Korea's equity market.
#YonhapInfomax #AimedBio #KOSDAQ #IPO #InstitutionalDemand #MiraeAssetSecurities #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=93166
AimedBio to List on KOSDAQ This Week—Five IPO Subscriptions, Two Institutional Bookbuildings Scheduled
AimedBio will debut on KOSDAQ this week, leading a busy IPO calendar with five retail subscriptions and two institutional bookbuildings, highlighting strong investor demand in South Korea's equity market.
South Korea’s IPO market sees Aromatica debut on KOSDAQ this week, with AIMEDBIO and Teraview Holdings opening retail subscriptions and eight firms launching institutional bookbuilding, highlighting robust capital market activity.
#YonhapInfomax #Aromatica #KOSDAQ #IPO #AIMEDBIO #InstitutionalBookbuilding #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=92047
Aromatica to List on KOSDAQ This Week—Two IPO Subscriptions, Eight Institutional Bookbuildings Scheduled
South Korea’s IPO market sees Aromatica debut on KOSDAQ this week, with AIMEDBIO and Teraview Holdings opening retail subscriptions and eight firms launching institutional bookbuilding, highlighting robust capital market activity.
SK Plasma and Aimed Bio have entered a joint development and licensing agreement to co-develop an ADC-based cancer drug, combining Aimed Bio's research with SK Plasma's clinical and commercialization expertise to target rare and intractable diseases.
#YonhapInfomax #SKPlasma #AimedBio #ADCTherapy #CancerDrug #Biopharmaceuticals #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=66632
SK Plasma Signs Joint Development Agreement with Aimed Bio for ADC-Based Cancer Drug
SK Plasma and Aimed Bio have entered a joint development and licensing agreement to co-develop an ADC-based cancer drug, combining Aimed Bio's research with SK Plasma's clinical and commercialization expertise to target rare and intractable diseases.
Yonhap Infomax News